TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31240435

Group type: EXPERIMENTAL
Intervention: First-degree relatives (FDRs) of probands with PC
Number of subjects: 4095

Group type: EXPERIMENTAL
Intervention: Second-degree relatives (SDRs) of probands with PC
Number of subjects: 4095

Group type: EXPERIMENTAL
Intervention: First cousins (FCs) of probands with PC
Number of subjects: 4095

Group type: EXPERIMENTAL
Intervention: First-degree relatives (FDRs) of female probands with PC
Number of subjects: 4095

Group type: EXPERIMENTAL
Intervention: Second-degree relatives (SDRs) of female probands with PC
Number of subjects: 4095

Group type: EXPERIMENTAL
Intervention: First cousins (FCs) of female probands with PC
Number of subjects: 4095

Group type: EXPERIMENTAL
Intervention: First-degree relatives (FDRs) of probands diagnosed at age < 65 years
Number of subjects: 4095

Group type: EXPERIMENTAL
Intervention: Second-degree relatives (SDRs) of probands diagnosed at age < 65 years
Number of subjects: 4095

Group type: EXPERIMENTAL
Intervention: First cousins (FCs) of probands diagnosed at age < 65 years
Number of subjects: 4095
Study: 28427872

Group type: EXPERIMENTAL
Intervention: Abduction brace
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antirotation sling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study: 25583616

Group type: EXPERIMENTAL
Intervention: Protocolized care
Number of subjects: 556

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 556
Study: 23646465

Group type: EXPERIMENTAL
Intervention: Xingpi Yang'er Granule (XYG)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Live Combined Bifidobacterium and Lactobacillus Tablets (Control)
Number of subjects: 120
Study: 21592337

Group type: EXPERIMENTAL
Intervention: Patient satisfaction ratings after individual primary care consultations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physician satisfaction ratings after individual primary care consultations
Number of subjects: 0
Study: 18377970

Group type: EXPERIMENTAL
Intervention: Action Schools! BC intervention (INT)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Usual practice (UP)
Number of subjects: 268
Study: 17137211

Group type: EXPERIMENTAL
Intervention: Telmisartan (40 mg once daily for 24 weeks)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Amlodipine (5 mg once daily for 24 weeks)
Number of subjects: 43
Study: 14594113

Group type: EXPERIMENTAL
Intervention: Flutamide (7 participants)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (7 participants)
Number of subjects: 14
Study: 11003445

Group type: EXPERIMENTAL
Intervention: Allergen-specific immunotherapy with birch pollen extract
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Allergen-specific immunotherapy with grass pollen extract
Number of subjects: 52
Study: 8622574

Group type: EXPERIMENTAL
Intervention: Cortisol 10 mg orally
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Psychosocial stress (Trier Social Stress Test)
Number of subjects: 53
Study: 1315685

Group type: EXPERIMENTAL
Intervention: 150 mg repirinast
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 300 mg repirinast
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 450 mg repirinast
Number of subjects: 12
Study: 3908675

Group type: EXPERIMENTAL
Intervention: fenoprofen calcium, 200 mg
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: fenoprofen calcium, 400 mg
Number of subjects: 85

Group type: COMPARATOR
Intervention: aspirin, 650 mg
Number of subjects: 85

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 85
Study: 31081596

Group type: EXPERIMENTAL
Intervention: Multicomponent sleep intervention
Number of subjects: 33

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 33
Study: 28734107

Group type: EXPERIMENTAL
Intervention: XRNTX 380 mg administered by gluteal injection at 4-week intervals (n=50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Matched placebo administered by gluteal injection at 4-week intervals (n=50)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: XRNTX 380 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 100
Study: 26569149

Group type: EXPERIMENTAL
Intervention: Rotigotine (1‐3 mg/24 h)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 24764585

Group type: EXPERIMENTAL
Intervention: Black raspberries (BRBs) - daily for 9 months, including BRB powder orally and two BRB suppositories at bedtime
Number of subjects: 14

Group type: COMPARATOR
Intervention: Oral placebo plus BRB suppositories
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Black raspberries (BRBs) - daily for 9 months
Number of subjects: 14
Study: 22613648

Group type: EXPERIMENTAL
Intervention: Phacotrabeculectomy
Number of subjects: 31

Group type: COMPARATOR
Intervention: Trabeculectomy
Number of subjects: 31
Study: 20569707

Group type: COMPARATOR
Intervention: Baseline Troponin T levels (undetectable)
Number of subjects: 1250

Group type: EXPERIMENTAL
Intervention: Baseline Troponin T levels (detectable but below median)
Number of subjects: 1250

Group type: EXPERIMENTAL
Intervention: Baseline Troponin T levels (above median)
Number of subjects: 1250

Group type: EXPERIMENTAL
Intervention: Combination of baseline TnT and ST-segment resolution (STRes)
Number of subjects: 1250
Study: 18313505

Group type: EXPERIMENTAL
Intervention: Oestrogen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other agents
Number of subjects: 0
Study: 15894560

Group type: EXPERIMENTAL
Intervention: Propofol-Lipuro (3 mg/kg)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Diprivan with added lidocaine (0.3 mg/kg)
Number of subjects: 83
Study: 11999563

Group type: EXPERIMENTAL
Intervention: G-CSF
Number of subjects: 64

Group type: COMPARATOR
Intervention: Chemotherapy alone (Control)
Number of subjects: 64
Study: 9809085

Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms.kg‐1
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms.kg‐1 plus dexamethasone 8 mg i.v.
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 135
Study: 7698516

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 31
Study: 2676966

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg methylphenidate
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 24
Study: 665535

Group type: EXPERIMENTAL
Intervention: Clonidine therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (after 3 days of therapy and again after 30 days)
Number of subjects: 20
Study: 30383467

Group type: EXPERIMENTAL
Intervention: IRD scale (intervention)
Number of subjects: 2380
Study: 30290667

Group type: EXPERIMENTAL
Intervention: Propofol total intravenous anesthesia
Number of subjects: 84

Group type: COMPARATOR
Intervention: Desflurane inhalation anesthesia
Number of subjects: 84
Study: 26828395

Group type: EXPERIMENTAL
Intervention: Character strengths‐based intervention using the Values in Action Inventory of Strengths for Youth
Number of subjects: 81

Group type: COMPARATOR
Intervention: Comparison group (control)
Number of subjects: 81
Study: 24754350

Group type: EXPERIMENTAL
Intervention: BoNT/A treatment (230 or 460 U onabotulinumtoxinA)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 52
Study: 22762347

Group type: EXPERIMENTAL
Intervention: 4 mm × 32 G pen needle
Number of subjects: 168

Group type: COMPARATOR
Intervention: 5 mm pen needle
Number of subjects: 168

Group type: COMPARATOR
Intervention: 8 mm pen needle
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: 4 mm pen needle
Number of subjects: 168
Study: 20740615

Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide (CYC) for 1 year
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide (CYC)
Number of subjects: 158
Study: 18071252

Group type: EXPERIMENTAL
Intervention: Cassis polysaccharide (CAPS)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 15776298

Group type: EXPERIMENTAL
Intervention: Blunt tapered needle
Number of subjects: 200

Group type: COMPARATOR
Intervention: Sharp needle
Number of subjects: 200
Study: 11976244

Group type: EXPERIMENTAL
Intervention: Eradication treatment (omeprazole 20 mg, metronidazole 500 mg, and clarithromycin 250 mg for 7 days)
Number of subjects: 294

Group type: COMPARATOR
Intervention: Placebo treatment (omeprazole 20 mg, placebo metronidazole, and placebo clarithromycin for 7 days)
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Eradication treatment
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Patients negative for H pylori
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Patients positive for H pylori
Number of subjects: 294
Study: 9917775

Group type: EXPERIMENTAL
Intervention: LASIK for myopia correction
Number of subjects: 574
Study: 7896490

Group type: EXPERIMENTAL
Intervention: estriol iontophoresis
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: tretinoin iontophoresis
Number of subjects: 46
Study: 1696577

Group type: EXPERIMENTAL
Intervention: Combination of antithrombin III and heparin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dextran 40
Number of subjects: 0
Study: 7016248

Group type: EXPERIMENTAL
Intervention: 10% podophyllin
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: 25% podophyllin
Number of subjects: 140

Group type: COMPARATOR
Intervention: Podophyllin treatment (10% and 25%)
Number of subjects: 140
Study: 31619437

Group type: EXPERIMENTAL
Intervention: 750 mg amoxicillin three times daily for three months
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 29037637

Group type: EXPERIMENTAL
Intervention: Yoga program (30 min per day, twice a week for 12 weeks)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 34
Study: 25646368

Group type: EXPERIMENTAL
Intervention: Debio0932 at a dose of 1000 mg daily
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Debio0932 at doses up to 1600 mg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Debio0932
Number of subjects: 50
Study: 25189750

Group type: EXPERIMENTAL
Intervention: Feedback from the system
Number of subjects: 16

Group type: COMPARATOR
Intervention: No feedback from the system
Number of subjects: 16
Study: 23061323

Group type: EXPERIMENTAL
Intervention: Ongoing counseling and methadone maintenance therapy
Number of subjects: 0
Study: 20083724

Group type: EXPERIMENTAL
Intervention: Potassium chloride
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Potassium bicarbonate
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 17377586

Group type: EXPERIMENTAL
Intervention: Thalidomide, doxorubicin, and dexamethasone (TAD)
Number of subjects: 398

Group type: COMPARATOR
Intervention: Vincristine, doxorubicin, and dexamethasone (VAD)
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Thalidomide as part of induction regimen
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Thalidomide patients
Number of subjects: 398
Study: 15934353

Group type: EXPERIMENTAL
Intervention: Fiber 7 supplement (7 g per meal twice a day)
Number of subjects: 92
Study: 12447093

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A injections
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lidocaine with steroid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10452746

Group type: EXPERIMENTAL
Intervention: Warming of feet in warm water (WW, 42 degrees C)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Room-temperature water (RW, 30 degrees C)
Number of subjects: 14
Study: 7844484

Group type: EXPERIMENTAL
Intervention: HEMSTIM program with anxiety-laden words (experimental group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: HEMSTIM program with neutral words (control group)
Number of subjects: 40
Study: 2189591

Group type: EXPERIMENTAL
Intervention: Etoposide (VP‐16) 100, 150, or 225 mg/m2 infused over 2 h into the pleural space after drainage of pleural fluid
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Etoposide (VP‐16) 225 mg/m2
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Etoposide (VP‐16)
Number of subjects: 10
Study: 7288177

Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 19200

Group type: COMPARATOR
Intervention: Control (unvaccinated)
Number of subjects: 19200

Group type: EXPERIMENTAL
Intervention: Strongly tuberculin-positive (Heaf Grades III-IV) children
Number of subjects: 19200
Study: 31751828

Group type: EXPERIMENTAL
Intervention: PM10 during dust days
Number of subjects: 0

Group type: COMPARATOR
Intervention: PM10 during non-dust days
Number of subjects: 0

Group type: COMPARATOR
Intervention: PM10 during dust days in Tehran
Number of subjects: 0

Group type: COMPARATOR
Intervention: PM10 during non-dust days in Tehran
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PM2.5 during non-dust days in Tehran at lag 2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PM2.5 during non-dust days in Tehran at lag 3
Number of subjects: 0

Group type: COMPARATOR
Intervention: PM2.5 in Ahvaz
Number of subjects: 0
Study: 30358864

Group type: EXPERIMENTAL
Intervention: Active tDCS (2-mA for 20 minutes/session, 10 sessions)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 21
Study: 27984230

Group type: COMPARATOR
Intervention: Wound Infiltration (15 mL of bupivacaine 0.25% in each side of the surgical wound, total 30 mL)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Transversus Abdominis Plane (TAP) Block (20 mL of bupivacaine 0.25% bilaterally, total 40 mL)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups (Wound Infiltration and TAP Block)
Number of subjects: 80
Study: 26216675

Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) 10 mg, bid for 3 months
Number of subjects: 120

Group type: COMPARATOR
Intervention: Indomethacin 25 mg, bid for 3 months
Number of subjects: 120

Group type: COMPARATOR
Intervention: Comparison between TAM and Indomethacin
Number of subjects: 120
Study: 24036568

Group type: EXPERIMENTAL
Intervention: mCABG
Number of subjects: 60

Group type: COMPARATOR
Intervention: cCABG
Number of subjects: 60
Study: 20801436

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone gel (TTG) pretreatment, 12.5 mg applied daily for 21 days before COS
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (no TTG pretreatment)
Number of subjects: 110
Study: 19373657

Group type: EXPERIMENTAL
Intervention: Thalidomide (200 mg/d, with dose escalation up to 1000 mg/d over 60 days)
Number of subjects: 28
Study: 17302070

Group type: EXPERIMENTAL
Intervention: Shuangfujin (SFJ)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Boric acid
Number of subjects: 120

Group type: COMPARATOR
Intervention: Pifukang lotion
Number of subjects: 120

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 120
Study: 16476934

Group type: EXPERIMENTAL
Intervention: Tetrabenazine (TBZ), maximum dosage of 100 mg/day for 12 weeks
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 12627850

Group type: EXPERIMENTAL
Intervention: G‐CSF (lenograstim)
Number of subjects: 84
Study: 10784622

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide plus G-CSF (regimen C)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Granulocyte-macrophage colony-stimulating factor plus G-CSF (regimen G)
Number of subjects: 29
Study: 8980158

Group type: EXPERIMENTAL
Intervention: GH replacement therapy
Number of subjects: 13
Study: 1459878

Group type: EXPERIMENTAL
Intervention: Moderate intensity aerobic exercise training program (8 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (n = 15)
Number of subjects: 40
Study: 6501754

Group type: EXPERIMENTAL
Intervention: Nutrient intakes of white girls
Number of subjects: 1247

Group type: EXPERIMENTAL
Intervention: Nutrient intakes of urban girls
Number of subjects: 1247

Group type: EXPERIMENTAL
Intervention: Folacin intake
Number of subjects: 1247

Group type: EXPERIMENTAL
Intervention: Calcium and magnesium intakes
Number of subjects: 1247

Group type: EXPERIMENTAL
Intervention: Overall nutrient intake
Number of subjects: 1247

Group type: EXPERIMENTAL
Intervention: Folacin, iodine, vitamin D, iron, calcium, vitamin B-6, zinc, magnesium, and vitamin A intakes
Number of subjects: 1247
Study: 30238430

Group type: EXPERIMENTAL
Intervention: Pheochromocytoma
Number of subjects: 240
Study: 28513635

Group type: EXPERIMENTAL
Intervention: Dark chocolate supplementation for 15 days
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo chocolate
Number of subjects: 110
Study: 24583745

Group type: EXPERIMENTAL
Intervention: Endocut mode (E‐mode)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Conventional blended cut mode (C‐mode)
Number of subjects: 360
Study: 24254262

Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate 400 mg bid plus amoxicillin 1 g bid plus clarithromycin 500 mg bid
Number of subjects: 279

Group type: COMPARATOR
Intervention: Lansoprazole 30 mg bid plus amoxicillin 1 g bid plus clarithromycin 500 mg bid
Number of subjects: 279
Study: 21875224

Group type: EXPERIMENTAL
Intervention: Placebo (believed to be methylphenidate)
Number of subjects: 96

Group type: COMPARATOR
Intervention: No medication (control group)
Number of subjects: 96
Study: 18357535

Group type: EXPERIMENTAL
Intervention: Prior practice with simulated machine operation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Feedback interpretation following simulations
Number of subjects: 0
Study: 17225018

Group type: EXPERIMENTAL
Intervention: Fucicort Lipid cream
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: Fucicort cream
Number of subjects: 629

Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 629
Study: 14717749

Group type: EXPERIMENTAL
Intervention: Ventilation scintigraphy after inhalation of technegas
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High resolution computed tomography (HRCT)
Number of subjects: 20
Study: 11771086

Group type: EXPERIMENTAL
Intervention: Trans-septal approach to the mitral valve
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard left atriotomy
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 9222077

Group type: EXPERIMENTAL
Intervention: Maalox (30 mL) with trovafloxacin (100 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo with trovafloxacin (100 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Maalox (30 mL) 2 h before trovafloxacin (100 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Omeprazole (40 mg) with trovafloxacin (100 mg)
Number of subjects: 12
Study: 8240996

Group type: EXPERIMENTAL
Intervention: Cisplatin plus etoposide (EP)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Carboplatin plus etoposide (EC)
Number of subjects: 62
Study: 3316304

Group type: EXPERIMENTAL
Intervention: Moxonidine
Number of subjects: 152

Group type: COMPARATOR
Intervention: Clonidine HCl
Number of subjects: 152
Study: 28668998

Group type: EXPERIMENTAL
Intervention: Magnesium-Zinc-Calcium-Vitamin D co-supplementation (100 mg magnesium, 4 mg zinc, 400 mg calcium, 200 IU vitamin D, twice a day for 12 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (twice a day for 12 weeks)
Number of subjects: 60
Study: 27599002

Group type: EXPERIMENTAL
Intervention: MTA Fillapex and gutta‐percha (group 1)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: AH Plus and gutta‐percha (group 2)
Number of subjects: 34

Group type: COMPARATOR
Intervention: MTA Fillapex
Number of subjects: 34
Study: 25651427

Group type: EXPERIMENTAL
Intervention: Dacetuzumab + R-ICE
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo + R-ICE
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Subsequent autologous stem cell transplant
Number of subjects: 151
Study: 24029165

Group type: EXPERIMENTAL
Intervention: Nicotine e‐cigarettes (16 mg)
Number of subjects: 657

Group type: COMPARATOR
Intervention: Nicotine patches (21 mg, one daily)
Number of subjects: 657

Group type: COMPARATOR
Intervention: Placebo e‐cigarettes (no nicotine)
Number of subjects: 657

Group type: COMPARATOR
Intervention: Nicotine e‐cigarettes vs patches
Number of subjects: 657

Group type: COMPARATOR
Intervention: Nicotine e‐cigarettes vs placebo e‐cigarettes
Number of subjects: 657

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 657
Study: 21086021

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 201
Study: 18997543

Group type: EXPERIMENTAL
Intervention: Hydroxypropyl-Guar (Systane)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normal saline solution
Number of subjects: 12
Study: 17058847

Group type: EXPERIMENTAL
Intervention: Combined Salmeterol/Fluticasone 50/250 mg for 6 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Salmeterol first or Fluticasone first for 4 weeks each
Number of subjects: 12
Study: 12752647

Group type: EXPERIMENTAL
Intervention: Glyde File Prep with 0.5 mL of 1% NaOCl irrigation after each file size and an additional final irrigation of 10 mL 1% NaOCl
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 17% EDTA with 0.5 mL of 1% NaOCl irrigation after each file size and an additional final irrigation of 10 mL 17% EDTA
Number of subjects: 39

Group type: COMPARATOR
Intervention: 1% NaOCl with 0.5 mL of 1% NaOCl irrigation after each file size and an additional final irrigation of 10 mL 1% NaOCl
Number of subjects: 39
Study: 11084130

Group type: EXPERIMENTAL
Intervention: Lichtenstein tension‐free hernioplasty (LH)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional Bassini hernia repair (BH)
Number of subjects: 30
Study: 9112326

Group type: EXPERIMENTAL
Intervention: Chymopapain for chemonucleolysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chymopapain injection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Collagenase for chemonucleolysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chondroitinase ABC
Number of subjects: 0
Study: 1602608

Group type: EXPERIMENTAL
Intervention: Leukocyte-depleted platelet concentrates prepared through a polyester platelet filter (Sepacell-PL)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Standard platelet concentrates (control group)
Number of subjects: 72
Study: 3912977

Group type: EXPERIMENTAL
Intervention: Acyclovir 10 mg/kg, 8‐hourly for 10 days
Number of subjects: 127

Group type: COMPARATOR
Intervention: Vidarabine 15 mg/kg daily for 10 days
Number of subjects: 127
Study: 30900380

Group type: EXPERIMENTAL
Intervention: 8-week mindfulness-based intervention (MBI)
Number of subjects: 143